Nicotinamide adenine dinucleotide (NAD +) is considered to be an important molecule for mitochondrial energy conversion and is closely related to health and disease. How AD+ enters the mitochondria has always been an unsolved mystery. Scientists have found related "transporters" in yeast and plant cells, but no such proteins have been found in mammalian cells.
Recently, the University of Pennsylvania published its latest findings in the journal Nature for the first time to identify mitochondrial NAD + transporters in human cells. The title of the article is "SLC25A51isamammalianmitochondrialNAD + transporter". Researchers found that after increasing SLC25A51, the concentration of NAD + in mitochondria increased significantly. On the contrary, in the absence of SLC25A51, the total amount of NAD + in the whole cell did not change, but the NAD + entering the mitochondria was significantly reduced, and the mitochondria decreased.
Oxygen consumption and the ability to produce ATP are both impaired. Isotope tracking technology shows that all NAD + in the mitochondria is transported from the cytoplasm, rather than synthesized in the mitochondria. The researchers said that with the first discovery of human cell mitochondrial NAD + transporter, the research is still in its infancy to protect human health and specifically treat certain diseases. He pointed out that through precise regulation of mitochondrial NAD + levels, there is hope for the future.